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dispose the kidney to glomerular hyperfiltration-related renalC-reactive protein is associated with renal function abnormali-
function loss.ties in a non-diabetic population.
Background. C-reactive protein (CRP) has recently been in-
troduced in cardiovascular medicine as a predictor of myocar-
dial infarction, stroke and peripheral artery disease in different
The risk of progressive atherosclerotic cardiovascularpopulations. We hypothesized that elevated CRP levels are as-
disease is determined by a set of classical risk factors suchsociated with renal function abnormalities.
Methods. To test this hypothesis, we studied the relationship as diabetes, hypertension, hyperlipidemia, smoking, obe-
between CRP levels and renal function loss measured as dimin- sity [1] and an elevated urinary albumin excretion [2].
ished creatinine clearance in a large non-diabetic population In addition, it has been shown that elevated serum levels(7317 subjects). In addition, the associations and confounding
of C-reactive protein (CRP) are present among subjectseffects of established renal risk factors that could explain the
at risk for future atherothrombotic disease in the coro-association between CRP and diminished renal filtration were
studied. Also, the association of CRP with early alterations in nary [3, 4], cerebral [5] and peripheral circulation [6],
renal function, such as those evidenced by a relatively high glo- independently of established cardiovascular risk factors.
merular filtration (“hyperfiltration”), was examined. CRP lev-
This led to the use of CRP as an additional marker ofels were divided in quartiles. Subjects with CRP levels within
progressive cardiovascular disease [7].the first quartile were defined as the reference group. Dimin-
ished renal filtration and hyperfiltration were defined as a creat- For progressive renal disease the classical risk factors
inine clearance below or exceeding two times the prediction include diabetes [8], hypertension [9], hyperlipidemia
interval of the age- and sex-related reference group. [10], smoking [11, 12], obesity [13] and an elevated uri-
Results. Elevated CRP levels were positively associated with
nary albumin excretion [8, 14]. However, the impact ofcardiovascular and renal risk factors: age, body mass index, blood
low-grade inflammation, as measured by a highly sensi-pressure, serum cholesterol level, smoking, plasma glucose level
and elevated urinary albumin excretion. Elevated CRP was posi- tive CRP method, is unknown in renal disease. We hy-
tively associated with diminished filtration (OR 1.8; 95% CI pothesized that CRP could play a role in renal disease
1.2 to 2.6). In multivariate analyses, CRP was independently in relation to progressive renal function loss.associated with a diminished filtration (OR 1.9; 95% CI 1.3 to
The mechanism of the relationship between CRP and2.9). Interestingly, CRP also was associated with hyperfiltration
progressive cardiovascular disease is assumed to be based(highest quartile, OR 1.7; 95% CI 1.2 to 2.5). However, body
mass index accounted for most of the relationship between on CRP representing a low-grade inflammatory state
CRP and hyperfiltration. either originating in the vasculature such as the endothe-
Conclusions. As in cardiovascular disease, CRP appears to be lium [15] or a systemic effect on the vasculature due toa risk marker for renal function loss. The mechanism of this re-
inflammatory mediators released elsewhere in the body,lationship remains to be clarified. However, the association be-
for example, fat tissue, or due to external stimuli suchtween CRP, body weight, and a relatively elevated creatinine
clearance is a hypothesis-generating finding, suggesting that as smoking [16]. In either mechanism interplay with such
early inflammatory processes related to high body fat may pre- risk factors probably occurs. No data or hypotheses on
a comparable relationship between CRP and risk factors
to our knowledge are available in progressive renal func-Key words: cardiovascular disease, nephropathy, glomerular filtration
rate, C-reactive protein, urinary albumin excretion. tion loss. CRP could provide a link between risk factors
for renal disease and renal function loss, since these con-
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plays an early role in risk for progressive kidney disease, pressures were calculated as the mean of the mean of the
last two out of ten measurements of both visits. Hyper-one may hypothesize that CRP is related to early indica-
tors for progressive renal function loss. A higher than nor- tension was defined as a systolic blood pressure 140
mm Hg or a diastolic blood pressure 90 mm Hg or themal glomerular filtration rate (“hyperfiltration”) is such
an early indicator of susceptibility for renal function loss use of antihypertensive medication. Body mass index
(BMI) was calculated as the ratio between weight andat least in diabetic subjects (non-insulin and insulin de-
pendent diabetes mellitus) [18] and hypertensive sub- the square of height (kg/m2). Obesity was defined as a
BMI 30 kg/m2 [21]. Hypercholesterolemia was definedjects [19].
To this end, we studied first the relationship between as a serum cholesterol level of6.5 mmol/L or the use of
lipid-lowering therapy. Smoking was defined as currentCRP and diminished glomerular filtration (measured as
creatinine clearance) in a large non-diabetic population, smoking. Urinary albumin excretion rate (UAE) was cal-
culated as the mean of two 24-hour UAE and groups wereand whether this is influenced by other renal risk factors
such as hypertension, hyperlipidemia, obesity, plasma defined as follows: normoalbuminuria (0 to 15 mg/24 h),
high-normal albuminuria (15 to 30 mg/24 h), micro-glucose and smoking, as well as elevated urinary albumin
excretion levels. Second, we investigated whether ele- albuminuria (30 to 300 mg/24 h) and macroalbuminuria
(300 mg/24 h). Body surface area (BSA) was calculatedvated CRP levels were associated with a relatively high
glomerular filtration in this population, and whether this according to DuBois and DuBois [22]. Creatinine clear-
ance was calculated by taking the mean of the two 24-relationship was influenced by renal risk factors as well.
hour urinary creatinine excretions divided by serum cre-
atinine and corrected for BSA (mL/min/1.73 m2). To
METHODS
identify the subjects with a relative low and high creati-
Study population and design nine clearance, the following procedure was used: a refer-
ence group of subjects were defined with CRP levelsThis cross-sectional study is part of the ongoing PRE-
VEND study (Prevention of Renal and Vascular ENd within the first quartile of the whole sample. In these
subjects, the regression of creatinine clearance by agestage Disease), conducted in Groningen, The Netherlands.
All inhabitants of the city of Groningen between the ages was calculated separately for men and women. Best fit-
ting was reached by including the quadratic term of ageof 28 and 75 years (85,421 subjects) were asked to send
in a morning urine sample and to fill out a short question- into the model, that is, a non-linear decrease in creatinine
clearance with increasing age (Fig. 1). Renal functionnaire. A total of 40,856 (47.8%) responded. From this
group, 30,890 subjects had a urinary albumin concentra- abnormalities, such as diminished filtration and hyperfil-
tration, were defined respectively as a creatinine clear-tion of 10 mg/L and 9966 subjects had a urinary albu-
min concentration of 10 mg/L in their morning urine ance below (N  244) or exceeding (N  229) the 95%
confidence interval (95% CI) of the individual meansample. After exclusion of subjects with insulin use and
pregnant women, all subjects with a urinary albumin (that is, prediction interval) of the age- and sex-related
reference group.excretion10 mg/L (N 7768) together with a randomly
selected control group with a urinary albumin concentra- Leukocyturia and/or erythrocyturia was defined as
either erythrocytes 50/L, or leukocytes 75/L, ortion of 10 mg/L (N  3395) were invited for further
investigation in an outpatient clinic. Finally, the actual leukocytes 75/L and erythrocytes5/L in the urine.
Diabetes was defined as a fasting plasma glucose levelcohort of 8592 subjects completed two visits. Measure-
ments performed were extensively described in previous 7.8 mmol/L or a non-fasting plasma glucose level
11.1 mmol/L or the use of antidiabetic medication.reports [14, 20]. Briefly, both visits consisted of anthropo-
metric measurements, supine blood pressure measure- Present renal disease was defined as prior dialysis treat-
ment and/or proteinuria as a consequence of renal dis-ments for ten minutes (Dynamap XL Model 9300 series
device), electrocardiography recordings (Cardio Control, ease reported by questionnaire.
Delft, The Netherlands), two 24-hour urine collections,
Laboratory methodsand fasting blood samples. All participants completed a
questionnaire on demographics and cardiovascular and Urinary albumin concentration was determined by
nephelometry with a threshold of 2.3 mg/L and intra-renal history. All participants gave written informed con-
sent. The PREVEND study was approved by the local and interassay coefficients of variation of 2.2% and
2.6%, respectively. High sensitive CRP was determinedmedical ethics committee and conducted in accordance
with the guidelines of the declaration of Helsinki. also by nephelometry with a threshold of 0.175 mg/L and
intra- and interassay coefficients of 4.4% and 5.7%,
Calculations and definitions respectively (BNII N; Dade Behring, Marburg, Ger-
many). CRP levels below the detection level thresholdC-reactive protein levels were divided in quartiles (de-
tailed in the Results section). Systolic and diastolic blood were scored as 0.18 mg/L. Plasma glucose, serum choles-
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distribution vs. high  highest quartile) and compared
with the other risk factors, for instance, obesity (no/yes).
When subjects with low CRP and low BMI are used
as reference (OR  1), one can estimate the relative
importance of high CRP and high BMI as risk factors
for either hyperfiltration or diminished filtration by com-
paring the odds ratios (OR) in high-CRP-low-BMI and
low-CRP-high-BMI categories.
Logistic regression analysis was used to test the associ-
ation among the CRP quartiles with hyperfiltration and
diminished filtration, respectively. After entering the
four CRP categories into the model, a further adjustment
was made for age and gender. Multivariate analyses in-
cluded all variables significantly associated with elevated
CRP levels according to Table 1.
Because 24-hour urine collection might be inaccurate
as a result of collection errors, we carried out a specific
validation step. Therefore, our data were analyzed after
excluding subjects who had a difference between their
24-hour creatinine clearance of the first urine collection
and of the second urine collection greater than twice
the standard deviation according to the Bland-Altman
method [23].
Our data were analyzed also with the exclusion of sub-
jects with a CRP level 10 mg/L (10 mg/L  96th per-
centile), taking into account the possible effect of in-
flammatory disease on renal function. Secondly, the data
were validated by analysis with creatinine clearance val-
ues not corrected for BSA. Thirdly, subjects with macro-
albuminuria were excluded to eliminate the potential for
severe and inflammatory primary renal disease. These
Fig. 1. Creatinine clearance as a function of age, with the prediction
validation steps did not materially affect the results and,interval representing subjects with hyperfiltration (above the upper
line) and subjects with diminished filtration (below the lower line). (A) therefore, the results for the total sample population are
Male subjects. (B) Female subjects. shown.
RESULTS
terol and serum and urinary creatinine were determined From the 8592 subjects studied, the exclusion criteria
by Kodak Ektachem dry chemistry (Eastman Kodak, were subjects with leukocyturia and/or erythrocyturia
Rochester, NY, USA). Urinary leukocyte and erythro- (N 451), diabetes mellitus (N 317) and renal disease
cyte measurements were done by Nephur-test  leuco (N  67). CRP levels could not be determined in 440
sticks (Boehringer Mannheim, Mannheim, Germany). subjects due to missing samples. Thus, the final analysis
included 7317 non-diabetic subjects.
Statistical analysis The characteristics of our study population according
All calculations were performed with SPSS version to the four quartiles of CRP are shown in Table 1. The
10.0 software (SPSS, Chicago, IL, USA). Continuous data following interquartile ranges were calculated: 1st quar-
are reported as mean  SD; skewed distributions are tile (0.18 to 0.54 mg/L), 2nd quartile (0.54 to 1.20), 3rd
presented as the median with the 25th and 75th percen- quartile (1.20 to 2.76) and 4th quartile (2.76). These
tiles. All P values are two-tailed. A P value of 0.05 interquartile ranges of CRP are in agreement with stud-
was considered statistically significant. Differences among ies investigating its association with cardiovascular dis-
CRP quartiles with other variables were assessed by 2 ease in apparently healthy men and women [4, 24]. Age,
analysis or analysis of variance (ANOVA). gender, BMI, systolic and diastolic blood pressures, use
To study the interaction of risk factors on the associa- of antihypertensive medication, cholesterol, lipid-lower-
tion between CRP and renal function abnormalities, CRP ing therapy, plasma glucose concentration, and smoking
showed a significant linear trend in the subsequent quar-was dichotomized (low  three lowest quartiles of the
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Table 1. Associations of C-reactive protein (CRP) categories with population variables tested for trend
Quartiles of CRP
1st 2nd 3rd 4th Uncorrected Corrected
0.18–0.54 mg/L 0.54–1.20 mg/L 1.20–2.76 mg/L 2.76 mg/L P value P valueb
C-reactive proteina mg/L 0.3 (0.2–0.4) 0.8 (0.7–1.0) 1.9 (1.8–2.3) 7.25 (3.7–83.4)
Male % 51.4 53.4 53.6 46.5 0.006
Age years 44 (11) 48 (12) 51 (13) 52 (13) 0.001
Body mass index kg/m2 23.6 (3.0) 25.5 (3.4) 26.8 (3.9) 27.8 (4.9) 0.001 0.001
Obesity % 3.0 9.3 19.1 27.0 0.001 0.001
Systolic BP mm Hg 121 (16) 128 (19) 131 (21) 134 (21) 0.001 0.001
Diastolic BP mm Hg 70 (9) 74 (10) 75 (10) 76 (10) 0.001 0.001
Antihypertensive therapy % 3.8 8.4 13.8 17.4 0.001 0.001
Hypertension % 13.7 26.9 36.9 41.6 0.001 0.001
Cholesterol mmol/L 5.3 (1.0) 5.6 (1.1) 5.8 (1.2) 5.8 (1.2) 0.001 0.001
Lipid-lowering therapy % 3.1 5.6 6.2 7.2 0.001 0.15
Hypercholesterolemia % 15.0 24.1 29.4 31.0 0.001 0.001
Glucose mmol/L 4.5 (0.6) 4.7 (0.6) 4.8 (0.7) 4.9 (0.8) 0.001 0.001
Smoking % 38.4 40.0 47.6 51.0 0.001 0.001
Urinary albumin excretiona mg/24 h 7.8 (5.9–12.0) 8.6 (6.0–14.8) 9.8 (6.4–18.4) 10.4 (6.6–24.8) 0.001 0.001
Creatinine clearance mL/min/1.73 m2 96 (19) 93 (20) 91 (21) 91 (23) 0.001 0.05
Diminished filtration % 2.5 3.0 4.1 4.3 0.001 0.001
Hyperfiltration % 2.7 3.3 2.6 4.5 0.001 0.001
a Urinary albumin excretion and CRP are expressed as median with the 25th–75th percentiles, because of skewed distribution
b Age and gender adjusted P value (for linear trend)
Table 2. Odds ratios of diminished filtration according totile of CRP. These differences remained statistically sig-
concentration of C-reactive protein
nificant after adjusting for age and gender for all vari-
Quartile of C-reactive protein mg/L, rangeables, except lipid-lowering therapy. Concerning renal
1 2 3 4characteristics, median levels of urinary albumin excre-
0.54 0.54–1.20 1.22–2.76 2.76tion significantly increased with increasing CRP quar-
Model 1 (OR) 1.0 1.3 1.6 1.8tiles, also after adjusting for age and gender. Further-
95% CI 0.9–1.9 1.1–2.4 1.2–2.6more, the mean values of creatinine clearance followed P NS 0.01 0.005
a negative trend in the subsequent CRP quartiles. Model 2 (OR) 1.0 1.4 1.9 2.1
95% CI 0.9–2.1 1.3–2.8 1.4–3.2The prevalence of diminished filtration as well as hy-
P NS 0.005 0.005perfiltration increased with each CRP quartile. Thus, the Model 3 (OR) 1.0 1.3 1.7 1.9
95% CI 0.8–2.0 1.1–2.5 1.3–2.9mean creatinine clearance in the higher CRP quartiles
P NS 0.05 0.005is partly the result of subjects with either hyperfiltration
Model definitions are: Model 1, crude odds ratios; Model 2, adjusted for ageor diminished filtration. Obviously, this mean value does
and gender; Model 3, Model 2 BMI, glucose, systolic and diastolic blood pres-
not provide optimal information about the true relation- sure, antihypertensive use, cholesterol, lipid-lowering therapy, albuminuria groups
and smoking.ship between CRP and creatinine clearance.
Diminished renal filtration
Univariate and multivariate models (Table 2) showed effect of elevated CRP was least in UAE groups 15 to
an elevated risk for diminished filtration in the third 30 and 30 to 300 mg/24 h with an overlap of confidence
[crude odds ratio (OR) 1.6, range 1.1 to 2.4; P  0.01] intervals. The point estimates of the data did not suggest
and fourth quartiles (crude OR 1.8, range 1.2 to 2.6; P synergistic effects of CRP and risk factors on the risk
0.005) of CRP, also after adjustment for age and gender. for diminished filtration. Thus, elevated CRP levels inde-
Further adjustment for potential confounders did not pendently contributed to the risk of diminished renal
markedly attenuate this relationship with an odds ratio filtration.
of 1.9 (1.3 to 2.9; P  0.005) in the highest quartile.
HyperfiltrationIn the lowest three quartiles of CRP, only hyperten-
sion was significantly related to diminished filtration, Univariate and multivariate models showed that the
whereas elevated UAE of 15 to 30 mg/24 h was nega- highest CRP quartile was associated with an elevated risk
tively associated (Table 3). As compared to subjects with for hyperfiltration compared with the reference group
low CRP, those with elevated CRP levels had an in- (crude OR 1.7, range 1.2 to 2.5; P  0.002), and also
creased risk for diminished filtration, both in the absence after adjustment for age and gender. However, BMI was
attributed in such a way to the relationship between CRPand in the presence of other risk factors. This additive
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Table 3. Joint effects of C-reactive protein and risk factors on the relative risk of diminished filtration
Risk factors Limits CRP 75th percentile CRP 75th percentile
Obesity No 1 1.51 (1.10–2.07)
Yes 1.18 (0.72–1.95) 1.66 (1.03–2.67)
Hypertension No 1 1.56 (1.10–2.22)
Yes 1.58 (1.09–2.27) 2.03 (1.32–3.14)
Hypercholesterolemia No 1 1.55 (1.11–2.15)
Yes 1.18 (0.81–1.72) 1.71 (1.08–2.71)
Smoking No 1 1.48 (0.97–2.26)
Yes 1.33 (0.97–1.82) 1.94 (1.34–2.81)
Glucose 5.1 mmol/La 1 1.54 (1.11–2.13)
5.1 mmol/L 0.84 (0.56–1.25) 1.27 (0.80–2.03)
Albuminuria 0–15 mg/24 h 1 1.72 (1.25–2.36)
15–30 mg/24 h 0.40 (0.20–0.79) 0.39 (0.12–1.25)
30–300 mg/24 h 1.30 (0.79–2.14) 1.36 (0.74–2.52)
Odds ratios (95% CI) are adjusted for age and gender in models.
a The cut-off point of glucose is based on the 75th percentile
and hyperfiltration that the statistical significance of the those subjects with clinical diabetic nephropathy. This
result is consistent with our finding of an association oflatter relationship was lost (OR 1.4, 0.9 to 2.0; NS). Ad-
justment for other potential confounders further attenu- high levels of CRP with diminished filtration. Reasons
for this discrepancy could be the following. First, ourated this relationship to an OR of 1.2 (0.7 to 1.9; NS).
No effect-modification was observed between risk fac- population sample is larger, which yields increased statis-
tical power. Second, we used a highly sensitive CRP assaytors and CRP on the risk of hyperfiltration, that is, no
synergistic effects of CRP and risk factors on the risk of in contrast with previous studies. These latter sensitive
assays have high analytical precision and determine CRPhyperfiltration were observed.
levels well within the normal range. Therefore, the in-
creased variance of the CRP data also yields more statis-
DISCUSSION tical power to detect small, but nonetheless important
The relationship between CRP and atherothrombotic associations. In agreement with our data is the study of
cardiovascular disease has been established in a number Panichi et al, who showed that CRP and IL-6 levels were
of cross-sectional [17, 25] and prospective studies in ap- inversely related with creatinine clearance in chronic
parently healthy subjects and in subjects with pre-exis- pre-dialysis patients [30].
tent cardiovascular disease [4, 24, 26, 27]. To our knowl- How should the observed associations between ele-
edge, the current study is the first to show that low-grade vated CRP levels, and cardiovascular and renal risk fac-
inflammation, as measured by a highly sensitive CRP tors be interpreted? Systemic inflammation at a low-grade
method, is independently associated with diminished re- level is held partly responsible for an excess of athero-
nal filtration in a large non-diabetic population. The fact sclerotic vascular disease. CRP is a very sensitive marker
that CRP was associated with higher than normal creati- of systemic inflammation. It is a major acute-phase pro-
nine clearances, this relationship being confounded by tein, which production by the (normal) liver is tightly
body mass, suggests that low-grade inflammation may regulated. In the presence of tissue injury or trauma, CRP
play a role in the susceptibility for, and possibly mainte- is quickly up-regulated, mainly in response to circulating
nance of, progressive renal disease. IL-6 [31]. Important sources of cytokine production are
Data concerning the role of low-grade inflammation adipose tissue [32] and smoking [25]. Increased fat mass
on renal function abnormalities are scarce. In a small is associated with increased endogenous production of
sample of type 2 diabetic subjects, Weiss et al showed that pro-inflammatory cytokines by adipocytes [32, 33], in-
elevated serum levels of neopterin, a monocyte activation cluding IL-6. The link between the acute-phase response
marker, and free pentosidine, an advanced glycosylation and obesity and its associated risk factors also is observed
end-product, predicted doubling of serum creatinine in at the epidemiological level [34]. Obesity, a strong corre-
four years [28]. Furthermore, in a small cross-sectional late of type 2 diabetes, is more and more believed to
study of Myrup et al, elevated levels of fibrinogen and predict end-stage renal disease and the development of
interleukin-6 (IL-6) were observed in type 1 diabetic overt proteinuria [35]. Smoking adversely affects pro-
gression of renal disease and the development of albu-subjects with diabetic nephropathy compared to control
subjects [29]. In both studies, no significant difference minuria in diabetic subjects [11] and non-diabetic sub-
jects [12]. Elevated cytokine levels also are associatedin CRP levels was observed between study groups. How-
ever, in both studies CRP levels tended to be higher in with the insulin resistance syndrome and associated fea-
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tures like hypertension and dyslipidemia [36]. Hyperten- did not attenuate or modify the association of CRP with
diminished filtration. Thus, our data do not support thatsion and hyperlipidemia are equally important in renal
disease progression [9, 10]. In our study, CRP was posi- CRP is a marker of albuminuria-induced renal injury.
Other studies support that CRP as a causative agenttively related to classical cardiovascular and renal risk
factors in a dose-dependent fashion. Interestingly, these could be involved in local renal inflammatory pathways.
Jabs et al showed that CRP is expressed by renal tubularpossible confounders could not account for the observed
link between inflammation and diminished filtration. cells after stimulation with tumor necrosis factor-	 or
interleukin-1	 in vivo, and in acutely rejected kidneyThus, CRP is independently associated with an impaired
filtration as it is also independently associated with car- allografts (abstract; J Am Soc Nephrol 12:A-3293, 2001).
They proposed that the acute-phase response not merelydiovascular disease in general [3, 4, 26, 27].
The relationship between elevated CRP levels and represents a systemic inflammatory reaction, but proba-
bly is part of and acts as a local inflammatory pathwayhyperfiltration, however, largely disappeared after ad-
justing for body mass index. There is a close relationship in the kidney. Also, it has been reported that CRP local-
izes in the kidney in various glomerular diseases in chil-between obesity and renal hyperfiltration [13, 37]. Poten-
tial mechanisms underlying this association are numer- dren [40].
A third explanation for the association between CRPous and include plasma volume expansion as a feature
of the insulin resistance syndrome. The virtual disappear- and diminished filtration could be the result of a decreased
renal clearance of CRP. However, the major determinantance of the association between CRP and renal hyperfil-
tration after adjustment for obesity is well in accordance of serum CRP concentration is its rate of synthesis by
the (normal) liver [41], and not excretion through thewith the previously described link between obesity and
the acute-phase response. However, this cross-sectional kidney. In patients with severe renal disease and in
healthy subjects, CRP is excreted in negligible amountsstudy cannot assess whether the observed relationship
of CRP with hyperfiltration is an epiphenomenon of the in the urine [42]. CRP can be filtrated, but like other
proteins it is reabsorbed by the tubulus. Thus, it is veryobese state or whether other processes related to obesity
are responsible. For example, insulin resistance, as a com- unlikely, though not excluded on these grounds, that the
relationship between CRP and diminished filtration ismon link, is tightly associated with obesity and renal hy-
perfiltration, as it is with a systemic low-grade inflam- explained just by a decrease in plasma clearance of CRP.
A fourth—and in our opinion the most likely—ex-matory response [36].
How should the data on the association between CRP planation of the association between CRP and dimin-
ished filtration is given by our finding of a relationshipand diminished renal filtration be interpreted? First, other
factors could provide an alternative explanation. Athero- between CRP and hyperfiltration and body weight. Early
inflammatory processes induced by overweight and/orsclerotic disease could be one of those factors, as elevated
cytokine and CRP levels are associated with (subclinical) smoking could damage the systemic and renal vascula-
ture, in the absence of any renal function abnormality.atherosclerotic disease and atherosclerotic disease activ-
ity [38]. In fact, atherosclerosis is an inflammatory disease In time, this could render the kidney more sensitive to
other damaging insults occurring in life. The result ofitself [15]. It may well be that arteriolosclerosis in the
renal vasculature is responsible for the observed rela- this could be the observed cross-sectional finding of CRP
being related to both diminished and high filtration.tionship. Other important mediators of vascular inflam-
mation also may be responsible for the observed rela- Another marker of cardiovascular and renal disease,
namely elevated urinary albumin levels, was associatedtionship between CRP and diminished filtration [17],
like atherogenic infections, endothelial dysfunction, and with CRP as shown previously in diabetic and non-dia-
betic subjects [43]. Both markers are associated withothers. For example, Rassu et al have demonstrated the
presence of Chlamydia pneumoniae in various athero- almost all of the previously mentioned risk factors, so they
may represent the same disease process. On the othersclerotic arteries including the renal artery [39]. Unfortu-
nately, the majority of available literature concerning hand, both CRP and microalbuminuria (UAE 30 to 300
mg/24 h) have been proposed as independent predictorsinflammation and vascular disease has focused on the
coronary circulation. of cardiovascular disease [2, 4, 44]. Our study suggests
that CRP and elevated UAE are independent and differ-Second, it might be that CRP is a marker of local in-
flammatory response in the kidney. Because of the cross- ent correlates of renal function abnormalities as well.
C-reactive protein is not only important because it hassectional design of this study, one has to consider the
possibility that renal function loss itself is an inflamma- provided insight into the pathophysiology of cardiovas-
cular disease, it may also serve as an early risk marker.tory condition. It is well known that gross albuminuria
(300 mg/24 h) is an important mediator of interstitial re- Investigators have begun seeking therapies that may
lower CRP concentrations and, presumably, cardiovas-nal inflammation. We showed that the presence of macro-
albuminuria and minor rises in urinary albumin excretion cular disease risk. Several agents, equally important in
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disease. Circulation 97:425–428, 1998sen, and calculated on a statistical basis rather than being
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measured in a more experimental design. In this epide- for global risk assessment in the primary prevention of cardiovascu-
lar disease. Circulation 103:1813–1818, 2001miological setting, however, we believe that these defini-
8. Viberti G: Etiology and prognostic significance of albuminuria intions are the best approximate measure of diminished
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